Document is current
Any future updates will be listed below
-
Authors
Gil-Torralvo, Ana https://orcid.org/0009-0000-9011-0446
Domínguez-Cejudo, M. Ángeles
Molina-Pinelo, Sonia https://orcid.org/0000-0002-5726-2453
Garrigós, Carmen https://orcid.org/0000-0003-1853-1822
Benavent-Viñuales, Marta https://orcid.org/0000-0003-1268-4588
Falcón, Alejandro https://orcid.org/0000-0003-4531-5877
Cejuela, Mónica https://orcid.org/0000-0002-3894-0765
Rodríguez-Alonso, Beatriz
Pascual, Javier https://orcid.org/0000-0003-3874-2782
Ruíz-Borrego, Manuel https://orcid.org/0000-0002-1181-5622
Salvador-Bofill, Javier
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche (PIP-0044-2020)
Consejería de Salud y Familias, Junta de Andalucía (RB-0003-2019 ; RC-0004-2020)
- License Information
-
More Information
Article History
Received: 24 November 2025
Accepted: 21 February 2026
First Online: 6 March 2026
Declarations
:
: A.G., M.B-V., A.F., M.C., B.R-A., J.P., M.R-B., and J.S-B. have received honoraria, travel support and/or consulting fees from pharmaceutical companies involved in breast cancer therapeutics, including Roche, Pfizer, Novartis, AstraZeneca and Daiichi-Sankyo. These activities are unrelated to the present work. All other authors declare no conflicts of interest.
: This study was approved by the Research Ethics Committee of the Virgen del Rocío Hospital (reference number 0920-N20) and was carried out in compliance with the principles of the Declaration of Helsinki and its amendments.
: All participants were informed about the objectives and procedures of the study and gave their informed consent in writing, and confidentiality and proper handling of personal data were guaranteed in all phases of the study.
